Navigation Links
Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF)

GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positive interim results from the ongoing Phase I study of its lead development programme, ALX-0081, an anti-thrombotic treatment. ALX-0081 is a novel ´first-in-class´ therapeutic Nanobody® targeting von Willebrand Factor (vWF), which can reduce the risk of thrombosis in patients with acute coronary syndrome.

The Phase I study in healthy volunteers is designed to assess safety, tolerability and pharmacokinetics of ALX-0081. It will also analyse pharmacodynamic effects of ALX-0081 to confirm its high potency. It is a double-blind, placebo-controlled trial in healthy male volunteers at a single center in Europe.

The study was initiated during the first quarter of 2007. The interim analysis indicates:

- the desired pharmacodynamic effect was observed as anticipated indicating the high potency of ALX-0081

- ALX-0081 was well tolerated and showed no serious adverse effects or dose limiting toxicity

The final results are anticipated to be available by the end of September 2007.

Dr Edwin Moses, CEO and Chairman said: "We are very encouraged by the positive results of our first Nanobody® in clinical development which is believed to be the first ever single domain antibody human trial. This is a significant milestone for Ablynx and demonstrates the success of Ablynx´s powerful discovery platform."

About ALX-0081
Through its novel, highly selective mode of action, ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications. Pre-clinical in vivo studies confirmed Ablynx´s belief that ALX-0081 has unique potential to set a new standard in anti-thrombotic therapy based on its immediate onset of action, its high potency and significantly improved safety compared to the currently marketed therapies in the form of significantly reduced bleeding complications. Ablynx has demonstrated a large therapeutic window for ALX-0081 based on the high efficacy and low bleeding demonstrated in primate studies, indicating a highly attractive drug profile.

Contacts:

At Ablynx:
Dr. Edwin Moses
Chairman and CEO
t : +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t : +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com


Visit our website: http://www.ablynx.com


The announcement distributed by Hugin directnews.
The issuer is solely responsible for the content of this announcement.

For address modifications please inform:

Tel.: 0049 (0) 341-2 24 56-30 or info@directnews.de
press kit: http://www.directnewsroom.de


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ALEXANDRIA, Va. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... year by the Academy of Managed Care Pharmacy ... care organizations can better address the opioid addiction ... Medication Assisted Therapies (MAT). ATAG,s newly ... in Improving Access to Naloxone," addresses many issues ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... , Dec. 2, 2016 CVS Health Corporation ... Analyst Day in New York City on Thursday, December 15, 2016, beginning ... leadership team will provide an in-depth review of the ... value. The company will also discuss 2017 earnings guidance ... webcast of the event will be broadcast simultaneously on ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 02, 2016 , ... Two years ago, Arizona State University ... live by 1 million viewers and won numerous honors, including the region’s top ... the Walter Cronkite School of Journalism and Mass Communication are following up their ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... "Pro3rd Accents ... FCPX editors to create versatile lower third titles with just a few clicks of ... Accents Volume 2 includes 30 lower third animations. Choose from various styles with accented ...
Breaking Medicine News(10 mins):